Co-promotion agreement to promote Prosed DS to urologists and retail pharmacists

Timm Medical Technologies, Inc., a specialist Urology company, announced today its exclusive co-promotion agreement with Ferring Pharmaceuticals Inc., a Swiss-based biopharmaceutical company, for Prosed® DS (methenamine, phenyl salicylate, methylene blue, benzoic acid, hyoscyamine sulfate) in the United States.

Under the agreement, Timm Medical will be responsible for promoting Prosed® DS to urologists and retail pharmacists in the United States. Ferring will continue to promote Prosed® DS to physicians in the United States and will retain responsibility for manufacturing, supply and regulatory affairs. Financial terms of the agreement were not disclosed.

Prosed® DS is a urinary analgesic, antiseptic and antispasmodic combination. Prosed® DS has a long history of use for the treatment of pain and discomfort of the lower urinary tract.

"We are excited to partner with Ferring Pharmaceuticals to promote this well-established treatment for urinary discomfort," commented David Talen, President of Timm Medical. "Timm Medical and Ferring Pharmaceuticals share a commitment to urologists and the care of their patients. Timm Medical's flagship product, the Osbon ErecAid, has a 30-year history of providing safe, effective and reliable treatment for men suffering from erectile dysfunction. Prosed® DS has the same outstanding reputation as an effective treatment for the pain associated with urological procedures, inflammatory diseases and infections, and represents a natural complement to our product portfolio."